Hepion Pharmaceuticals Inc. (HEPA) stock rises during pre market session. What has been happening lately?
Hepion Pharmaceuticals Inc. (NASDAQ: HEPA) stock declined by 5.23% at last close whereas the HEPA stock price soars by 3.07% in the pre market trading session. CRV431, Hepion Pharmaceuticals’ lead drug candidate, is a powerful inhibitor of cyclophilins, which play a role in a variety of diseases. CRV431 is currently in clinical trials for the […]
What’s driving Hepion Pharmaceuticals, Inc.’s (NASDAQ:HEPA) share price on post-market sessions?
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)stock surged 24.52% to $2.59 in the late hours last night after its Topline results have been announced from the Phase’s low dose cohort 2a ‘AMPITION’ clinical trial of CRV431, a novel cyclophilin inhibitor orally administered once daily.Phase 2a study of CRV431 is continuing at a higher dose of 225 mg, with […]
